The Michigan Center for Therapeutic Innovation (MCTI) and Fast Forward Medical Innovation (FFMI) offer a five-year, $2.5 million fund created to accelerate the discovery and translation of therapeutic candidates at the University of Michigan.
The fund supports the discovery and optimization of small molecule lead compounds for projects with a specific, novel, and testable drug discovery hypothesis. Selected projects receive funding and resources from MCTI in the areas of drug design, cell biology, medicinal chemistry, structural biology, and pharmacology (up to $150,000 in value for each award for a period of 18 months with the funds being disbursed in two stages). The fund is jointly administered by MCTI and FFMI.
An advisory committee of recognized drug discovery and development experts review and select projects for funding, and MCTI and FFMI will solicit experienced mentors to help guide funded project teams as required.
Deadline – Friday, September 8, 2017 at 5pm EST
A pre-submission application and meeting must be completed on or before August 25, 2017, before submitting a full proposal. The pre-submission template and instructions can be found on UMMS Competition Space. Please contact Ester Fernandez-Salas, MCTI Managing Director at email@example.com, Jason Rech, MCTI Managing Director of Chemistry at firstname.lastname@example.org, or Visha Krishnan, FFMI Sr. Business Analyst at email@example.com to arrange a pre-submission meeting.
Joseph Holoshitz, Internal Medicine – Rheumatology
Orally available small molecule lead for rheumatoid arthritis and other bone-damaging conditions
Peter Higgins, Internal Medicine, Gastroenterology
Optimization of novel Bcl-2/Bcl-xL inhibitors for anti-fibrotic activity and gut selectivity in the mouse Salmonella model of intestinal fibrosis
Zaneta Nikolovska-Coleska, Pathology
Small molecule Mcl-1 inhibitors for the treatment of cancer
Peter Arvan & Ming Liu, Division of Metabolism, Endocrinology, & Diabetes (MEND)
Pro-insulin Dimerization Surface Protectors (PDSPs)
Yali Dou, Pathology
Targeting SET domain of MLL family histone methyltransferases
Nouri Neamati, Pharmacy/Med Chem
Development of First-in-Class SHMT2 and MTHFD2 inhibitors